ARCHIVES

FDA carries Action On Two Cancer Drugs Over To 1996

This article is from The Cancer Letter archive.

Vol. 22 No. 01 | January 5, 1996

Download PDF Visit The Full Archive

Related Articles

Research Policy: NIH Trials Don’t Enroll Enough Women to Allow Analysis, GAO Says in Report

May 12, 2000

Conversations With The Cancer Letter: Youle: ACS Stance on Tobacco Sales Is Clear

April 18, 2014

NCI Intramural Budget And List Of Highest-Funded Branches, Laboratories

April 21, 1995

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

In Brief: OSCC Staff Appointments Announced Report Available On Chemical Disposal Health Aspects

August 3, 1984

FDA Approves Rituxan For CLL

February 19, 2010